Brodalumab + Brodalumab

ApprovedActive
0 watching 0 views this week๐Ÿ”ฅ Hot
80
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Psoriasis

Conditions

Psoriasis

Trial Timeline

Jan 24, 2020 โ†’ Jun 1, 2029

About Brodalumab + Brodalumab

Brodalumab + Brodalumab is a approved stage product being developed by Bausch Health for Psoriasis. The current trial status is active. This product is registered under clinical trial identifier NCT03240809. Target conditions include Psoriasis.

Hype Score Breakdown

Clinical
30
Activity
20
Company
5
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT03240809ApprovedActive

Competing Products

20 competing products in Psoriasis

See all competitors
ProductCompanyStageHype Score
Ixekizumab + PlaceboEli LillyPhase 2
52
VTX958 Dose A + VTX958 Dose B + VTX958 Dose C + VTX958 Dose D + PlaceboVentyx BiosciencesPhase 2
47
LY2525623 Intravenous + LY2525623 Subcutaneous + Placebo Intravenous + Placebo SubcutaneousEli LillyPhase 2
52
IxekizumabEli LillyPhase 3
77
80 mg Ixekizumab Dosing Regimens 1, 2, and 3 + PlaceboEli LillyPhase 3
77
Placebo + BaricitinibEli LillyPhase 2
52
CT-P43 + StelaraCelltrionPhase 3
77
CT-P17 + EU-approved HumiraCelltrionPhase 3
77
CT-P55 + EU-approved CosentyxCelltrionPhase 3
77
AMG 139AstraZenecaPhase 1
33
alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
85
alefaceptAstellas PharmaPhase 2
52
Tacrolimus CreamAstellas PharmaPhase 3
77
alefaceptAstellas PharmaPhase 3
77
peficitinib + PlaceboAstellas PharmaPhase 2
52
AlefaceptAstellas PharmaPhase 3
77
Amevive exposureAstellas PharmaPre-clinical
23
alefacept + placeboAstellas PharmaPhase 3
77
alefaceptAstellas PharmaApproved
85
ASKP1240 + PlaceboAstellas PharmaPhase 2
52